Evolocumab treatment for @ weeks resulted in significant ( p < @ ) mean ( @ % confidence interval ) dose-related reductions in Lp ( a ) compared to control : @ % ( @ % to @ % ) and @ % ( @ % to @ % ) with @ mg and @ mg , dosed every @ and @ weeks , respectively , with no plateau of effect .